Randomized Controlled Trial of Surfactant Administration by Laryngeal Mask Airway (LMA)

NATerminatedINTERVENTIONAL

Enrollment

380

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

December 31, 2009

Conditions

Respiratory Distress Syndrome, Newborn

Interventions

DEVICE

Surfactant administered via Laryngeal Mask Airway (LMA)

Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.

OTHER

standard of care (nasal CPAP and supplemental oxygen)

Standard of care will be utilized which may mean surfactant is administered

Trial Locations (1)

University of Virginia, Charlottesville